Search NLS News

XNK Therapeutics has announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible, states the company. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following […]

Clinical phase I data on Orion’s ODM-208 were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). “ODM-208 is a first-in-class CYP11A1-inhibitor and we are excited that this novel approach works in some of the patients who have only a few effective treatment options available. The first results of CYPIDES are […]

Recipharm has announced the acquisition of Arranta Bio, an advanced therapy CDMO, and Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners. The acquisition of Arranta Bio forms a cornerstone of Recipharm’s strategy to provide innovative drug developers in the biologics market with scientifically differentiated contract development and manufacturing services for ATMPs […]

BioInvent International has announced the appointment of Marie Moores as Chief Operating Officer. Marie Moores joined the company on February 1, 2022, and she will be involved in all operational aspects including quality assurance as well as commercial strategy planning such as further developing the target product profiles for BioInvent’s drug candidates. Marie Moores Marie […]

Xbrane Biopharma’s efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused. Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of Spherotide, a long-acting triptorelin formulation candidate intended to be used in treatment of prostate […]

The female sex hormone oestrogen may have protective effect against becoming seriously ill and dying in COVID-19, according to a Umeå University study. “The results are interesting enough to warrant further clinical studies. However, it is absolutely inappropriate to start experimenting with supplements yourself because oestrogen can also cause a number of more or less […]

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. “Saphnelo is the first new medicine for systemic lupus erythematosus to gain approval in Europe in over a decade and is the only […]

Trends within our industry tend to emerge slowly, and as a consequence of many small, intertwined developments that remain unnoticed as individual factors. At some point, however, the many small incremental changes come together to form a mosaic that emerges clearly. Once you see it, it appears obvious. You think, “How did I not see […]

Elypta has announced the launch of a clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study, LEVANTIS-0087A (LEV87A), aims to detect any-type cancer in adults who show no symptoms or have any recent history of cancer. […]

Xbrane Biopharma has reported results from the 12-months data from the Phase III equivalence trial Xplore with the Lucentis biosimilar candidate Xlucane. These data support the ongoing registration process for Xlucane, states the company. As previously announced, Xlucane met the primary endpoint demonstrating equivalent efficacy in the change of BCVA (Best Corrected Visual Acuity) at […]